EAU24 Expert Review | Professor Qiang Wei: Multimodal Treatment of Renal Cancer from a Surgical Perspective

EAU24 Expert Review | Professor Qiang Wei: Multimodal Treatment of Renal Cancer from a Surgical Perspective

The treatment of renal cancer includes surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. With advancements in treatment technologies, combining the latest modalities for comprehensive treatment of renal cancer is crucial for improving prognosis. The 39th Annual European Association of Urology (EAU24) Congress was held from April 5-8, 2024, in Paris, France, focusing on global urological oncology hotspots and forefront advancements from Chinese urological scholars. "Oncology Frontier" had the opportunity to interview Professor Qiang Wei from West China Hospital, Sichuan University, who shared insights into adjuvant immunotherapy for renal cancer, cytoreductive nephrectomy research, and robot-assisted radical nephrectomy.
Professor Wenbin Qian: Mechanisms of CAR-T Cell Therapy Resistance and Countermeasures | 2024 Nanjing Lymphoma Forum

Professor Wenbin Qian: Mechanisms of CAR-T Cell Therapy Resistance and Countermeasures | 2024 Nanjing Lymphoma Forum

Chimeric Antigen Receptor T-cell Therapy (CAR-T) is a novel cellular immunotherapy technology that has shown excellent efficacy in the treatment of refractory relapsed diffuse large B-cell lymphoma (DLBCL). Despite this, a significant number of patients do not respond to the treatment or experience relapse and progression. How to further improve the efficacy of CAR-T cells is a key focus of future research. At the recently held "2024 Nanjing Lymphoma Forum," Professor Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine delivered a brilliant report titled "Mechanisms of CAR-T Resistance Based on DLBCL Pathological Characteristics and Countermeasures." After the conference, "Oncology Frontier - Hematologie Frontier" invited Professor Wenbin Qian for an interview to further discuss this topic.
Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis

Effectiveness and Safety of Direct Oral Anticoagulants in the Treatment of Visceral Vein Thrombosis

The "Hepatology Digest - Liver Vascular Diseases" column is a scholarly column co-initiated by Dr. Xingshun Qi from the Department of Gastroenterology at the General Hospital of Northern Theater Command, at the invitation of the editorial board of Hepatology Digest. This column regularly collects and summarizes research progress in the field of liver vascular diseases, selecting and discussing one significant paper every two weeks (Wednesday). The aim is to help readers understand the reasoning behind the findings, inspire clinical research thinking, and apply what they have learned in practice.
Hepatol Int | 24-Hour Comprehensive Lifestyle Interventions Help Prevent and Control MAFLD

Hepatol Int | 24-Hour Comprehensive Lifestyle Interventions Help Prevent and Control MAFLD

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide, with recent data showing prevalence rates of up to 39% in adults and 20% in children. MAFLD is characterized by overweight or obesity, type 2 diabetes, and/or metabolically dysregulated hepatic steatosis and can coexist with various hepatic and cardiovascular metabolic diseases.
Prof. Pengfei Qiu: Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?

Prof. Pengfei Qiu: Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?

The axillary lymph node burden after neoadjuvant therapy is closely related to prognosis. Unlike the assessment in initial surgery patients, residual tumor cells after neoadjuvant therapy are considered resistant cells. Thus, can limited sentinel lymph node biopsy (SLNB) metastasis after neoadjuvant therapy exempt patients from axillary lymph node dissection (ALND)? At the 2024 South-North Forum, Prof. Pengfei Qiu from Shandong Cancer Hospital presented a report titled "Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?" This article reviews the key points of his lecture.
Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure

Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure

Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK, from April 14th to 17th, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with blood disorders. At this conference, a team led by Professor Yuqian Sun from Peking University People's Hospital presented their findings in an oral report titled "Salvage Haploidentical Transplantation with Flu/Cy Regimen and Donor Switching After Primary Graft Failure: Follow-Up Results," which garnered significant attention. Professor Sun was invited to share the main results of this study and the progress in salvage treatments for graft failure after haploidentical allogeneic hematopoietic stem cell transplantation.
2024 South-North Forum | Prof. Junjie Li: What’s Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?

2024 South-North Forum | Prof. Junjie Li: What’s Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?

Targeted therapy has always been a critical component of systemic treatment for HER2-positive breast cancer patients. Currently, small-molecule tyrosine kinase inhibitors (TKIs) are commonly used HER2-targeted therapies. What role do TKIs play in the neoadjuvant treatment of HER2-positive breast cancer, and what drug combinations yield the best treatment outcomes? At the 2024 South-North Forum, Prof. Junjie Li from Fudan University Cancer Hospital presented a report titled "What's Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?" This article compiles the key points from his lecture.
Professor Wenjun Zhang: Focusing on Clinical Application, Key Updates in the 2024 CSCO CAR-T Cell Therapy Guidelines | 2024 CSCO Guidelines Conference

Professor Wenjun Zhang: Focusing on Clinical Application, Key Updates in the 2024 CSCO CAR-T Cell Therapy Guidelines | 2024 CSCO Guidelines Conference

As scheduled, the 2024 China Society of Clinical Oncology (CSCO) guidelines conference has arrived, with many CSCO oncology treatment guidelines being updated or published for the first time. In the field of hematologic oncology, the much-anticipated CAR-T cell therapy guidelines have been significantly updated. The "CSCO CAR-T Cell Therapy for Malignant Hematological Diseases and Management of Related Infections Guidelines 2023" (referred to as the 2023 Guidelines) has been renamed to "CSCO CAR-T Cell Therapy for Malignant Hematological Diseases Guidelines 2024" (referred to as the 2024 Guidelines). At the conference, Professor Wenjun Zhang from Tongji Hospital affiliated with Tongji University and the Tongji University Institute of Hematology shared the key updates of the 2024 Guidelines. The highlights are organized below for our readers.

A Case of Extensive Portal Venous System Thrombosis and Prehepatic Portal Hypertension Following Transition from Low to High Altitude

To broaden the horizons and enrich the practical knowledge of clinical hepatologists, and to cultivate clinical thinking abilities, International Liver Disease has invited Professor Shanhong Tang’s team from the Department of Gastroenterology at Western Theater Command General Hospital to create the “Liver Difficult Cases” column. This column compiles "classic cases" encountered by Professor Tang’s team over years of clinical practice and treatment, and will also regularly collect complex or rare clinical cases published in renowned academic journals, emphasizing the diagnostic and therapeutic approaches for various liver diseases, providing valuable clinical references for peers.
Professor Jianming Guo : Enhancing Perioperative Predictive Performance for Kidney Cancer Patients with AI-Assisted Surgical Scoring Systems

Professor Jianming Guo : Enhancing Perioperative Predictive Performance for Kidney Cancer Patients with AI-Assisted Surgical Scoring Systems

Kidney cancer surgical scoring systems provide critical information for treatment planning, surgical method selection, tumor recurrence risk, and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from April 5 to 8, 2024, in Paris, France, where numerous studies and advancements related to kidney cancer surgery were presented. Oncology Frontier invited Professor Jianming Guo from Zhongshan Hospital, Fudan University, to share insights on preoperative and postoperative scoring systems, AI predictions of kidney tumor pathology, and prognosis.